Friday, 14 Dec 2018

You are here

The Benefits of a Lupus Clinic

A comparative cohort study assessing the quality of care in patients with systemic lupus erythematosus (SLE) suggests that a dedicated lupus clinic has better quality measure performance compared to lupus management in a general rheumatology clinic.

A study from Rush University enrolled 150 consecutive SLE patients - with 73 followed in the general rheumatology clinic and 77 followed in a dedicated lupus clinic. 

SLE patients seen in the lupus clinic had significantly better overall quality measure performance (85.8% versus 70.2%; P = 0.001).

Differences between the 2 groups showed that the lupus clinic outperformed the general rheumatology clinic in:

  • sunscreen counseling (98.7% and 83.6%; P = 0.001)
  • antiphospholipid antibody testing (71.4% and 37%; P < 0.001)
  • pneumococcal vaccination (84.8% and 48.8%; P < 0.001)
  • bone mineral density testing (94.2% and 54.5%; P < 0.001)
  • drug counseling (92.2% and 80.8%, P = 0.04)
  • steroid‐sparing (100% and 82%;P < 0.007);
  • angiotensin‐converting enzyme inhibitor use (94.4% and 58.3%; P = 0.03)
  • cardiovascular disease risk assessment (40.3% and 15.1%; P = 0.01).
  • They found a moderate correlation between physician volume and quality measure performance (ρ = 0.48, P < 0.001).

A dedicated lupus clinic appears to provide more comprehensive lupus care. These measures need to be considered by general rheumatologist for enhanced incorporation into their practices or alternatively consider the need for a focused lupus clinic in their overall care model. 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Genetic Diagnosis for Previously Undiagnosed Disorders

The NEJM has reported the NIH's Undiagnosed Diseases Network (UDN) study results of genetically identifying new diseases from prospectively followed persons with undiagnosed disorders. The UDN was formed in 2014 as a network of seven clinical sites, two sequencing cores, a coordinating center, central biorepository, a metabolomics core, and a model organisms screening center. It was established to apply a multidisciplinary model in the evaluation of the most challenging cases and to identify the biologic characteristics of newly discovered diseases.

SLE and Risk of Malignancy

The risk for cancer in systemic lupus erythematosus (SLE) patients has been inconsistently studied.  A new metanalysis shows that SLE has an increased risk for 16 specific cancers and decreased risk for prostate cancer and cutaneous melanoma. 

Diagnosing Early Lupus from Mimics

A multicenter study of early systemic lupus erythematosus (SLE) patients examined manifestations at disease onset and found that certain clinical features can help to distinguish early SLE from other SLE‐mimicking conditions. 

High CV Risk in Lupus

Patients with systemic lupus erythematosus (SLE) remain at risk for accelerated atherosclerosis, and important questions have yet to be answered, British investigators reported.

AURA-LV Trial - Voclosporin Effective in Lupus Nephritis

The AURA-LV trial assessed voclosporin, a calcineurin inhibitor in patients with active lupus nephritis (LN) and found that low-dose voclosporin may be successfully added to mycophenolate mofetil and corticosteroids to controll active LN.